Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
On July 25, according to the CDE official website, the clinical trial application for "OriC613 Injection" by Oricell Therapeutics was accepted, intended for the treatment of advanced pancreatic cancer.
OriC613 Injection aims to target two key targets, MSLN and CLDN18.2, to stimulate the patient's own immune system to attack and eliminate cancer cells.
OriC613 Injection Utilizes QrigincellTherapeutics' Unique CAR-T Cell Design
According to the pipeline information on the company's official website, apart from OriC613, several other pipelines of Oricell Therapeutics in the field of solid tumor treatment are also at different stages of progress.
OriCAR-017：Targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma (R/R MM). The first CAR-T product in China and the second globally targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma. Clinical research data was accepted for oral presentation at the 2022 ASCO Annual Meeting and the 2022 EHA Annual Meeting. Subsequently, the product received orphan drug designation from the U.S. FDA in October 2022, and follow-up data was published in January 2023 in the international clinical medical journal, The Lancet Haematology. The project has been approved by the NMPA to conduct Phase I of the registration clinical trial. The U.S. IND application is currently in progress.Ori-C101：Treatment of advanced primary hepatocellular carcinoma (HCC). Ori-C101 injection, which possesses independent intellectual property rights, features a highly specific and high-affinity full human antibody sequence targeting GPC3 and a unique signal activation component, Ori. It is intended for the treatment of adult patients with advanced hepatocellular carcinoma. The product has shown positive data in exploratory clinical studies and was accepted for publication at the 2021 ASCO Annual Meeting. Currently, a Phase I clinical trial in China has been initiated at Zhongshan Hospital Affiliated to Fudan University, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, and West China Hospital of Sichuan University.
1. Qrigincell Therapeutics Official Website
